Evaluation of the anti-peristaltic effect of glucagon and hyoscine on the small bowel: comparison of intravenous and intramuscular drug administration

What Was Tested

The paper reports a study of Glucagon, published as a randomized controlled trial.

• Anti-persitaltic agents are widely used before various diagnostic procedures of the abdomen. • The combination of iv-glucagon with im-hyoscine provides reliable spasmolysis with early onset. • Intravenous spasmolysis is more reliable compared to intramuscular administration. • Intravenous glucagon has a prolonged spasmolytic effect compared to intravenous hyoscine.

Who Took Part

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Six volunteers underwent Magnetic Resonance Imaging (MRI) after standardized oral preparation in random order five separate MR examinations with both spasmolytic agents (HBB intravenous(i.v.) or intramuscular(i.m.), GLU i.v. or i.m., and a combined scheme).

How the Study Was Run

The design is described as randomized.

Random assignment meant chance, not the researchers, decided who got Glucagon and who got the comparison, which limits bias.

The MR protocol included a sagittal 2D cross-section of the small bowel with a temporal resolution of 0.55 s acquired over 60 to 90 min.

To quantify bowel motility, small bowel cross-sectional areas were summated over time.

What Was Measured

Topics PubMed links to this paper include Antidiarrheals, Gastrointestinal Motility, Glucagon, Image Enhancement, Intestine, Small, Magnetic Resonance Imaging and Reproducibility of Results.

What This Means in Plain Language

The paper is a randomized study of Glucagon.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2012 (European radiology), a journal based in Germany.

More context: the Glucagon compound page, all human trials.